共 55 条
[1]
Brodoefel H(2010)Early and late-onset acute GvHD following hematopoietic cell transplantation: CT features of gastrointestinal involvement with clinical and pathological correlation Eur J Radiol 73 594-600
[2]
Bethge W(2006)Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2137-2150
[3]
Vogel M(2009)Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis J Hematol Oncol 2 13-2413
[4]
Kamangar F(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-1966
[5]
Dores GM(2007)Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960-533
[6]
Anderson WF(2007)Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase III trials Cancer 110 525-5518
[7]
Goulart BH(2009)Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 5513-3785
[8]
Clark JW(2008)Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 82-3516
[9]
Lauwers GY(2009)Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group J Clin Oncol 27 3778-141
[10]
Burris HA(2005)Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 3509-312